1. Introduction {#sec1}
===============

Hemorrhagic chronic radiation proctopathy (CRP) is a common complication after pelvic radiotherapy. It had an incidence of 5% to 15% in the patients of pelvic cancers within 6 months after radiotherapy \[[@B1]\]. Multiple factors were involved in the pathogenesis of hemorrhagic CRP, like mucosal damage, microvascular injury with tissue ischemia, and telangiectasias \[[@B2]\]. Oral or enema treatment with salicylates, corticosteroids, and sucralfate usually had a limited benefit. Moreover, surgery was not recommended for a high incidence of morbidity \[[@B3]\]. However, hyperbaric oxygen therapy (HOT) and formalin application were reported to be effective in radiation proctitis \[[@B3]--[@B8]\]. As an easy method in destructing the telangiectasias caused by radiotherapy, argon plasma coagulation (APC) was reported to have a better efficacy than formalin in treating hemorrhagic CRP (79% versus 27%, *P* = 0.017) \[[@B4]\]. Alvaro et al. also found that APC therapy had a significantly better response than hyperbaric oxygen therapy in reducing blood transfusion and tissue toxicity, although both treatments showed no significant difference in resolving rectal bleeding. In spite of this, several studies still reported a high incidence of up to 20% in APC-associated complications, such as ulcers, perforations, strictures, and fistulas \[[@B5]--[@B10]\]. Furthermore, Sato et al. found that appropriate APC settings (e.g., electric power, application time, and argon flow rate) could reduce the damage to deeper tissues, thus decreasing the incidence of complications \[[@B11]\]. However, its effectiveness and safety were not clearly assessed in previous studies. Therefore, we conducted a systematic review to evaluate the efficacy and safety of APC in treating hemorrhagic CRP.

2. Methods {#sec2}
==========

2.1. Medical Literature Search {#sec2.1}
------------------------------

The databases of PubMed, Embase, and Cochrane Library were searched for relevant studies from inception to July 2017, using the key words including "radiation proctopathy" \[MeSH Terms\] OR ("radiation" \[All Fields\] AND "proctopathy" \[All Fields\]) OR "radiation proctopathy" \[All Fields\] OR ("radiation proctitis" \[MeSH Terms\]) OR ("radiation" \[All Fields\] AND "proctitis"\[All Fields\]) OR ("radiation proctitis" \[All Fields\]) AND ("Argon plasma coagulation therapy" \[MeSH Terms\] OR ("Argon plasma coagulation" \[All Fields\] AND "therapy" \[All Fields\]) OR "Argon plasma coagulation therapy" \[All Fields\]) OR ("APC therapy"\[MeSH Terms\]) OR ("APC therapy" \[All Fields\]). There was no language restriction for literature search.

2.2. Selection Criteria and Exclusion Criteria {#sec2.2}
----------------------------------------------

All the studies were reviewed independently by two investigators. Studies were included if fulfilling the following criteria: (i) including patients with pelvic cancers and subsequent radiotherapy, (ii) diagnosed as hemorrhagic CRP, and (iii) evaluated the efficacy and safety of APC. The exclusion criteria were as follows: reviews, case reports, animal studies, and studies without full text or sufficient data.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

The following information was extracted from each included study: author, year of publication, area, study design, number of cases, age, gender, cancer type, follow-up time, argon gas flow rate and electric power of APC, number of rectal bleeding cessation (NRBC), hemoglobin (LHb) levels, and short-term and long-term complications. The quality of included studies were assessed using an adjusted version of the Newcastle-Ottawa Scale, which contained a cohort selection on APC administration and its representativeness, ascertainment of APC exposure, and evidence that there was no prior exposure to APC, outcome, longevity follow-up (at least 6 weeks), and bias due to dropout or incomplete follow-up \[[@B12]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

The efficacy of APC therapy was evaluated according to the degree of improvement in rectal bleeding and hemoglobin, while the safety was assessed based on the incidence of complications, which were categorized as short term (e.g., urgency, diarrhea, incontinence, fever, anal or abdominal pain, and perforation) and long term (e.g., stenosis/strictures, rectal ulcers, recurrence of rectal bleeding, and fistula). As for APC settings, electric power, argon gas flow, and coagulation time were included analysis. Studies with a score of ≥5 were considered as high quality, with 3-4 for moderate quality. Discrepancies of assessments were resolved through discussion.

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

Of the 167 papers identified at the initial search, after removing the duplicates and exclusion of irrelevant studies, comments, case reports, and reviews, 37 studies were selected for the review of the full text. Another 4 studies were excluded due to the absence of certain interested outcomes including rectal bleeding cessation, the improvement of hemoglobin, and short-term and long-term complications, and 33 studies were included in the final review ([Figure 1](#fig1){ref-type="fig"}). All included studies including prospective (*n* = 21) and retrospective (*n* = 8) uncontrolled cohort trials, and 4 nonrandomized control trials \[[@B4], [@B13]--[@B15]\], were conducted at a single academic center. The average time of follow-up was 28 months (1 month to 170 months) ([Table 1](#tab1){ref-type="table"}). All patients with chronic radiation proctitis were characterized by rectal bleeding, which was referred to as hemorrhagic CRP.

3.2. Efficacy of APC {#sec3.2}
--------------------

The improvements in rectal bleeding and hemoglobin were regarded as efficacy of APC treatment, which were observed in 821 and 383 patients, respectively. 15 studies reported the improvement of hemoglobin after APC administration. [Table 2](#tab2){ref-type="table"} demonstrates that after APC treatment, the mean of hemoglobin levels was improved from 7.7--13.4 g/L to 11--14 g/L. 33 studies documented rectal bleeding cessation as evidenced in [Table 2](#tab2){ref-type="table"}, 5 of which had a 100% hemostasis rate \[[@B5], [@B7]--[@B9], [@B16]\]. Furthermore, in the largest study, Sato et al. \[[@B11]\] reported that during a mean follow-up of 34.6 months, 4 patients (6.3%) had minor recurrent rectal bleeding and 60 (93.8%) remained in remission. (*P* = 0.002) ([Table 2](#tab2){ref-type="table"}).

3.3. Safety of APC {#sec3.3}
------------------

APC-associated short-term and long-term complications were shown in [Table 3](#tab3){ref-type="table"}. Short-term complications were reported in 31 studies, while long-term complications in 33 studies and no complication in 11 studies. The incidence of complications was 0--63.6%. Especially in a study from Venkatesh and Ramanujam, USA, there was no complication among 40 patients after APC therapy \[[@B17]\], because the team had experience. The commonest procedure-related short-term complications reported were anal or rectal pain with or without tenesmus, which was most likely to occur following treatment near the dentate line. Abdominal bloating, vomiting, adynamic ileus, vagal symptoms, cramping, incontinence, fever, and colonic explosion were also reported. Necrosis of the lower part of the rectum was reported in one study \[[@B10]\]. The severe complication of perforation was reported in 2 series \[[@B10], [@B18]\], the incidence of which was 3.7% (1/27) and 3.3% (1/30), respectively. Ben-Soussan et al. reported that one patient had, during APC, colonic explosion which immediately led to a perforation \[[@B18]\]. The patient needed surgical treatment and made a complete recovery in 2 weeks. At the same time, Ben mentioned that the incidence of bowel explosion was higher after local preparation in comparison with oral reparation (*P* \< 0.05). Enema preparation with persistent solid stool above the coagulated lesions contributed to the main risk of perforation. Canard et al. also reported 1 perforation \[[@B10]\]. But we could not obtain the detailed information about the treatment of perforation and prognosis of the patient from their study. Grund et al. reported 1600 applications of APC for a variety of indications in the upper and lower gastrointestinal tract and reported a perforation rate of 0.31% \[[@B19]\].

Rectal ulcers, stenosis, and recurrence of rectal bleeding were common long-term complications following APC treatment. Chruscielewska-Kiliszek et al. reported rectal ulcers in 35 (56.5%) of 62 patients \[[@B20]\], an incidence that was relatively high in comparison with the reported overall rate of about 3.3% (1/30) \[[@B14]\]---21.4% \[[@B13]\] ([Table 3](#tab3){ref-type="table"}) in other series. Rectal ulcers developing during APC could be considered a consequence of thermal injury to already damaged and vascularly compromised tissue that was thus more fragile and had poorer healing \[[@B21]\]. The fact that rectal ulcers were not clinically troublesome meant they should not be considered an absolute contraindication to APC nor do they necessarily require any additional endoscopic follow-up \[[@B22]\]. The occurrence of stenosis compared with rectal ulcer was less common. The incidence of rectal stenosis varied among different studies, many studies describing no occurrence of rectal stricture while few studies reporting such complication in 2% (1/49) \[[@B23]\]---13.3% (2/15) \[[@B7]\]. However, given the fact that most of the rectal strictures were asymptomatic, their true incidence was difficult to estimate and theoretically would be higher than reported by several studies. The recurrence rate of rectal bleeding ranged from 2.1% (1/48) \[[@B24]\] to 6.3% (1/16) \[[@B6]\]. Patients on anticoagulants or aspirin were more likely to relapse. Kaassis et al. reported that patients who were receiving anticoagulation therapy required more APC sessions but could also achieve an equivalent therapeutic efficacy as those who were not on anticoagulation \[[@B6]\].

3.4. Arguments of APC Setting {#sec3.4}
-----------------------------

By reviewing relative literatures, we realized that different studies had different optional APC settings. This systematic review showed arguments of APC settings in 32 trials ([Table 1](#tab1){ref-type="table"}). The electric power setting ranged from 25 to 80 W (median 50 W), with an argon flow rate from 0.6 to 3.0 L/min (median 1.5 L/min). Of 10 trials that reported the records of coagulation time, only one trial briefly provided the specific number of coagulation time. The range of coagulation time was from 0.5 s to 3 s. Among included studies that observed incidence of complications, regardless of the range of electric power setting (30--50 W versus 50--80 W), the corresponding rate of complications had no difference (0--58.1% versus 0--63.6%). Even with the same power (60 W) and the flow rate \> 1.5 L/min, 4 series, respectively, reported complications in 0%, 35.7%, 0%, and 13.3% \[[@B5], [@B7], [@B13], [@B25]\]. In addition, there were no uniform settings of APC in 5 series which reported 100% hemostasis rate. Therefore, APC settings appeared to be uncorrelated with the incidence of complications in our study.

3.5. Quality Assessment {#sec3.5}
-----------------------

The quality assessment of studies using NOS is shown in [Table 4](#tab4){ref-type="table"}. The qualities of studies were considered high for 31 studies and moderate for 2 studies.

4. Discussion {#sec4}
=============

Chronic radiation proctopathy had an incidence of 5%--15% in patients with pelvic radiotherapy, and rectal bleeding was the most common complication. Radiation injury to the rectal wall became apparent like obliterative endarteritis with secondary tissue ischemic and development of neovascular mucosal lesions. These ones could bleed in a delayed fashion and different amounts: from little sporadic spotting which leads, sometimes to chronic anemia state, to episodes of severe rectal bleeding \[[@B26]\].

APC is a nontouch electrocoagulation technique in which high-frequency alternating current can be delivered to the target lesion by ionized gas. The limited depth of coagulation (0.5--3 mm) \[[@B27]\] explained the low risk of perforation, stenosis, and fistulization. Unlike traditional bipolar devices, APC could be applied axially and radially, allowing tangential coagulation of lesions around rectal bends without significant reduction in effectiveness. Moreover, the APC generator is mobile and can be used quickly at any place or time \[[@B28]\]. Thus, APC is a well-established treatment for various conditions, such as oozing hemorrhage from angiodysplastic lesions or polypectomy sites.

Our study firstly confirmed that APC was an effective and safe therapy in endoscopically treating hemorrhagic CRP. APC therapy had a high success rate of hemostasis and low incidence of complications, which could help improve the hemoglobin levels. Furthermore, APC therapy could be performed at the outpatient clinics because no sedation or analgesia was required during the procedure \[[@B29]\]. Sedation with midazolam, fentanyl, or propofol was administrated to minimize the discomfort caused by the lesions near dentate line or gaseous distension of the rectum \[[@B7], [@B9], [@B30]\].

Several studies reported that all patients had a decrease in transfusional requirements and an improvement in anemia \[[@B6], [@B7], [@B10], [@B16], [@B25]\]. The median lowest hemoglobin levels were 9.6 g/dL (range 5.1--14.1) before APC and the median improvement in hemoglobin levels after treatment was 2.05 g/dL (range 0.5--5.1) in a study by Hortelano et al. \[[@B14]\]. As for safety, more than ten studies reported no complication during the follow-up \[[@B5], [@B15]--[@B17], [@B25], [@B31]--[@B36]\]. However, several studies reported a low incidence of complications, including rectal or anal pain, recurrence of bleeding, rectal ulceration, and anal or rectal strictures. Rectal pain usually occurred near the dentate line after APC treatment \[[@B9]\]. It could be resolved spontaneously within a few days or with standard analgesics \[[@B9], [@B10], [@B29]\]. Recurrence of rectal bleeding was most likely to happen when patients were on anticoagulants or aspirin, and it also could be successfully treated after additional APC treatment. Although rectal ulcer and stenosis were common long-term complications, they were generally asymptomatic and did not require any additional endoscopic follow-up. In this systematic review, necrosis of the lower part of the rectum was reported in only one study \[[@B10]\]. 2 studies \[[@B10], [@B18]\] reported perforation following APC with low incidence. Ben et al. reported that one patient sustained a colonic explosion complicated by perforation that needed urgent surgery. The pathophysiology of the colon explosion remained unclear, but an accumulation of colonic gas (hydrogen and methane) at potentially explosive concentrations \[[@B37]--[@B39]\] could be the cause, especially the presence of stools above the lesions.

The optimal number of treatment sessions was still unknown. APC was traditionally not applied in one treatment session, particularly in patients with severe diseases. For therapeutic success, the median number of sessions per patient ranged from 1 to 3.7. Swan et al. \[[@B23]\] documented that there was a significant improvement in rectal bleeding among 68% of patients after the first session and 96% after two sessions. Karamanolis et al. \[[@B40]\] reported that APC with 2 sessions could resolve rectal bleeding completely in 89.3% (50/56) patients. According to this systematic review, the mean value of APC sessions was 1.9.

As for APC setting, there was still no consensus for the optimal APC settings (power and gas flow rate) for successful and safe coagulation. Sato et al. \[[@B11]\] reported that the ideal coagulation time was 2 seconds from an ex vivo experiment on swine rectal mucosa. Weiner et al. \[[@B41]\] also found the impact of coagulation time on the depth and diameter of the coagulation zone and reported that as coagulation time and electric power increase, at larger electric power (\>75 W) and/or longer coagulation time (\>3 s), the formation of craters and artificial clefts in submucosa and perforation increase. Because the data of coagulation time were not available in included studies, we could not conduct an analysis which could explain the effect of coagulation time on the depth. To sum up, coagulation time ranged from 0.5 s to 3 s in our study. Canard et al. reported that lower power settings were subscribed for a lower complication rate and decreased number of treatment sessions required for complete coagulation, with almost all complications occurring at power settings above 45 W \[[@B10]\]. We generally thought that lower power settings caused less injury, while in this systematic review, APC settings seemed to have no impact on complications.

We intended to further study the difference between the ICC system (e.g., first-generation APC) and the second-generation APC. Unfortunately, all of the trials included used the ICC system with parameter settings that were distinctly different from the second-generation APC. Compared with the ICC system, the second-generation APC offered a broader bandwidth of parameters including different APC modes and a range of power settings from 1 to 120 W \[[@B42]\]. Different APC modes appeared to be safe and effective in a variety of gastrointestinal conditions \[[@B43], [@B44]\].

Other than APC, salicylates, corticosteroids, sucralfate, and short-chain fatty acid enemas have been used with limited success, but hyperbaric oxygen therapy (HOT) and formalin application were shown to be effective in radiation proctitis \[[@B4], [@B5], [@B45]--[@B48]\].

The mechanism of HOT in treating radiation tissue injury was the induction of neovascularization which could reverse tissue hypoxia. Macrophages responding to the oxygen gradient between the damaged hypoxic cells and the surrounding normal tissue mediated the stimulus for angiogenesis \[[@B49]\]. Tahir et al. \[[@B50]\] reported a 95% efficacy of HOT for hemorrhagic CRP, where around half of the cases had a durable major response. Some patients even experienced symptom relief lasting as long as seven years. However, before consenting to HOT, patients should consider these factors: (1) Pressure inside the hyperbaric chamber can damage the middle and inner ear, nasal sinuses, lungs, and teeth in both adults and children. (2) Some people experienced claustrophobia inside the chamber. (3) The therapy might affect your eyes, for example, by promoting nearsightedness or cataract growth. (4) Diabetics should have their levels checked before and after treatment, because hyperbaric oxygen therapy affects blood sugar levels. (5) The cost of HOT was high enough, and it was not widely applicable. There was no uniformity in the methods of HOT. Although it could be perceived from the studies that HOT was useful in refractory radiation proctitis, there was marked variation between the studies \[[@B48], [@B50]--[@B53]\]. The reported number of HOT sessions for a successful treatment ranges from 12 to 90. Recently, a double-blind, sham-controlled, phase-3 randomized trial conducted by Glover et al. \[[@B54]\] reported that there was no significant difference between APC and HOT in rectal bleeding. Álvaro-Villegas et al. reported that APC and HOT were similar in treating rectal bleeding, while response rate was higher and faster in the APC group \[[@B13]\].

Formalin was a mixture of methanol and formaldehyde which covalently binded to proteins and causes cell necrosis. It acted as a hemostatic agent causing chemical cauterization to control bleeding from telangiectatic mucosal and submucosal vessels. In 1986, Rubinstein et al. were the first to use formalin for a hemorrhagic CRP patient to get a good response \[[@B55]\]. Most used 4% dilute formalin applied to the rectum mucosa either by direct application of formalin-soaked gauze or by "instilling" the solution in single or multiple aliquots down the operating channel of a colonoscope. Guo et al. in their randomized trial which randomly divided 122 patients into 4% or 10% formalin application showed that 10% formalin was associated with complications and 4% formalin should be the choice for treating hemorrhagic CRP \[[@B56]\]. Alfadhli et al. \[[@B4]\] compared the efficacy of formalin instillation therapy with APC therapy and found that APC showed a better efficacy (78.5% versus 27%). Nevertheless, the study of Yeoh et al. \[[@B57]\] found that there was no statistical difference between the APC group and the formalin group (94% versus 100%, respectively). It was worth noting that in formalin therapy, 18% of the patients underwent intestinal stricture and 21% with fecal incontinence \[[@B58]\]. Therefore, formalin might be proper for patients with proctitis and refractoriness to other endoscopy therapies, like argon plasma coagulation, rather than an upfront approach.

Any randomized control trials on APC in treating hemorrhagic CRP could not be available, which had the underlying methodological limitations in this systematic review. In addition, individual patient data (IPD) from eligible trials on APC were not available because it might not be possible to contact the original trial authors or authors might not be willing to share the raw data. Furthermore, we included several trials published early.

In conclusion, APC is a safe and effective method for treating hemorrhagic CRP. Further evidence from randomized controlled trials and comparative studies is required to confirm the role of APC and APC settings, and APC should be considered as a first-line therapy for hemorrhagic CRP.
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###### 

Characteristics of studies included in the systematic review.

  First author (year, area)       Study design    Age             Cancer types                                                                                          No. of patients   Electric power (W: watt)   Argon gas flow rate (L/min)   Rate of complication   Frequencies of session   Rate of hemostasis   Follow-up (m: month)    Loss-up
  ------------------------------- --------------- --------------- ----------------------------------------------------------------------------------------------------- ----------------- -------------------------- ----------------------------- ---------------------- ------------------------ -------------------- ----------------------- ---------
  Higuera (2004, Spain)           Retrospective   67.8 (58--76)   Cervical (1), endometrial (6), \>and prostate (3) cancer                                              10                60                         1.5--2                        0.0%                   1.9 (1--4)               78.6                 31.8 m (10--45 m)       0
  Alfadhli (2008, Kuwait)         Prospective     74.7            na                                                                                                    14                45--50                     1.2--2                        14.3%                  1.78                     85.7                 3 m                     0
  Alvaro (2011, Mexico)           Prospective     59.3 ± 12       na                                                                                                    14                60                         1.6                           35.7%                  3 ± 1                    92.6                 3 m                     0
  Ben (2004, France)              Prospective     73.1 (53--86)   Prostate (19), anal (4), uterine (3), and rectal (1) cancer                                           27                40--50                     0.8--1                        18.5%                  2.66 (1--7)              92.9                 13.6 m (3--31 m)        0
  Canard (2003, France)           Prospective     70.7 (58--85)   Prostate (23), uterine (4), cervical (1), and squamous-cell anus (1) cancer and uterine (1) sarcoma   30                42 (30--80)                1.5 (0.8--1.2)                26.7%                  69, 2.3 (1--5)           95.2                 1--35 m                 2
  Chruscielewska (2013, Poland)   Prospective     65.5 ± 10.9     Cervical (16), endometrial (17), prostate (28), and rectal (1) cancer                                 62                25--40                     1.5--2/1--1.5                 58.1%                  2 (1--3)                 91.7                 52 weeks                0
  Chutkan (1997, USA)             Prospective     72 (64--85)     Prostate (10) and uterine (2) cancer                                                                  12                na                         na                            0.0%                   1 (1-2)                  97.9                 6.6 m (3--13 m)         0
  Dees (2006, Netherlands)        Prospective     73.6 (59--89)   Prostate (45), urinary bladder (4), and uterine cervix (1) cancer                                     50                50                         2                             2.0%                   3 (1--6)                 100                  na                      2
  Fantin (1999, Switzerland)      Retrospective   na              Prostate (6) and endometrial cancer (1)                                                               7                 60                         3                             0.0%                   2 (2--4)                 90                   24 m (18--24 m)         0
  Hortelano (2014, Spain)         Retrospective   70 (56--78)     Prostate cancer                                                                                       30                50                         1.8                           6.67%                  3                        76.7                 14.5 m (2--61 m)        0
  Kaassis (2000, France)          Retrospective   73.5 (62--80)   Prostate (15) and uterine (1) cancer                                                                  16                40                         0.6                           31.3%                  3.7                      93.8                 10.7 m (8--28 m)        0
  Karamanolis (2009, Greece)      Prospective     68.4 (45--86)   Prostate cancer                                                                                       56                40                         2                             5.4%                   2 (1--8)                 89.3                 17.9 m (12--33 m)       0
  Latorre (2008, Spain)           Prospective     70.9 ± 7.38     na                                                                                                    38                50--60                     1.4--1.8                      0.0%                   3.6 ± 2.7                86.8                 28.5 ± 3.9 m            0
  Lenz (2011, Brazil)             Prospective     70.4 ± 11.1     Prostate (8), cervical (5), and endometrial (2) cancer                                                15                40                         1                             40%                    3.7 ± 1.7                93.3                 12.5 m (2--30 m)        0
  Lpoez (2010, Mexico)            Retrospective   64 (25--80)     Cervicouterine (5), endometrial (2), vaginal (2), prostate (9), and colorectal (1) cancer             19                40--50                     1--1.5                        5.3%                   2 (1--7)                 94.7                 29 m (1--93 m)          0
  Onoyama (2011, Japan)           Prospective     74 ± 5.5        Prostate cancer                                                                                       24                30--40                     1                             0.0%                   (1--7)                   100                  23.5 m (1--53 m)        0
  Rolachon (2000, France)         Prospective     70.3 ± 10       Prostate (11) and endometrial (1) cancer                                                              12                50                         1                             25.0%                  2.8 ± 0.8                91.7                 6 m                     0
  Rotondano (2003, Italy)         Prospective     69.2 (22--81)   Endometrial (13), cervical (6), and prostate (5) cancer                                               24                40                         0.8--1.2                      25.0%                  69, 2.5 (1--6)           91.7                 41 m (24--60 m)         0
  Sait (2013, Turkey)             Retrospective   61              Prostate (6), rectum (2), cervix (12), and endometrium (1) cancer                                     21                50 (40--60)                1.5 (1.2--2)                  23.8%                  3 (1--11)                85.7                 34.6 m                  0
  Samy (2012, Egypt)              Prospective     na              na                                                                                                    23                40--50                     0.8--1.0                      0.0%                   na                       73.9                 37 m (6--84 m)          0
  Sarah (2001, France)            Prospective     73 ± 3          Prostate (9), uterine (1), and rectal (1) cancer                                                      11                50                         0.8--2                        63.6%                  3.2 ± 0.4                100                  19 ± 2 m                0
  Sato (2011, Japan)              Prospective     72 (35--83)     Prostate (46) and cervical (19) cancer                                                                65                40                         1.2                           18.5%                  2 (1--5)                 93.8                 34.6 m (3.6--121.1 m)   0
  Sebastian (2004, Ireland)       Prospective     69 (53--77)     Prostate (23) and bladder (2) cancer                                                                  25                30 (25--50)                1.5                           0.0%                   1 (1--4)                 84                   14 m                    0
  Silva (1999, Portugal)          Prospective     65 (42--77)     Cervical (17), endometrial (7), and prostate (4) cancer                                               28                50                         1.5                           10.8%                  2.9 (1--8)               96.4                 10 m (1--15 m)          0
  Smith (2001, USA)               Prospective     na              Prostate cancer                                                                                       7                 40--45                     1.6                           0.0%                   1--3                     71.4                 4--13 m                 0
  Swan (2010, Australia)          Prospective     72.1 (51--87)   Prostate (45), uterine (2), cervical (2), and vaginal (1) cancer                                      50                50                         1.4--2.0                      36.0%                  1.36 (1--3)              98                   20.6 m (5--48 m)        1
  Takemoto (2012, Japan)          Prospective     na              Prostate cancer                                                                                       12                30--40                     1                             0.0%                   (1--3)                   83.3                 35 m (12--69 m)         0
  Tam (2000, Australia)           Retrospective   na              Prostate (14) and cervical (1) cancer                                                                 15                60                         2                             13.3%                  2 (1--4)                 100                  24 m (8--35 m)          0
  Tjandra (2001, Australia)       Prospective     73 (62--78)     Prostate (10) and cervix (2) cancer                                                                   12                40                         1.5                           0.0%                   na                       50                   11 m (4--17 m)          0
  Venkatesh (2002, USA)           Prospective     64--83          na                                                                                                    40                40--60                     1.5                           0.0%                   na                       97.5                 3--30 m                 0
  Villavicencio (2002, USA)       Prospective     72.6 (58--86)   Prostate (15), endometrial (4), sacral chondroma (1), and cervical (1) cancer                         21                45--50                     1.2--2                        19.0%                  1.7 (1--4)               100                  10.5 m (1--29 m)        0
  Yeoh (2013, Australia)          Prospective     73 (49--87)     Prostate cancer                                                                                       17                60--80                     2                             0.0%                   2                        94.1                 110 m (29--170 m)       0
  Zinicola (2003, Italy)          Retrospective   68 (30--80)     Prostate (8), cervical (4), and bladder (2) cancer                                                    14                65                         2                             7.1%                   2.0 (1--4)               83.3                 19 m (5--41 m)          2

###### 

Study characteristics of selected studies on the levels of hemoglobin and rectal bleeding before and after APC administration.

  Author                Year   Type of study   Proctitis                                 Total number of bleeding   Number of rebleeding   Rate of hemostasis (%)   Mean level of hemoglobin before APC (g/dL) ± SD   Mean level of hemoglobin after APC (g/dL) ± SD
  --------------------- ------ --------------- ----------------------------------------- -------------------------- ---------------------- ------------------------ ------------------------------------------------- ------------------------------------------------
  Alfadhli              2008   Prospective     Prospective                               14                         3                      78.6                     na                                                na
  Álvaro-Villegas       2011   Prospective     Chronic radiation proctitis               14                         2                      85.7                     9.9 ± 2.3                                         11.3 ± 2
  Ben                   2004   Prospective     Hemorrhagic radiation proctitis           27                         2                      92.6                     na                                                na
  Canard                2003   Prospective     Radiation proctitis                       28                         2                      92.9                     na                                                na
  Chruscielewska        2013   Prospective     Chronic radiation proctitis               62                         3                      95.2                     13.07 ± 1.73                                      13.96 ± 1.44
  Chutkan               1997   Prospective     Proctitis                                 12                         1                      91.7                     na                                                na
  Dees                  2006   Prospective     Chronic radiation proctitis               48                         1                      97.9                     na                                                na
  Fantin                1999   Retrospective   Proctitis                                 7                          0                      100.0                    na                                                na
  de la Serna Higuera   2004   Retrospective   Hemorrhagic radiation proctopathy         10                         1                      90.0                     na                                                na
  Hortelano             2013   Prospective     Chronic radiation proctitis               30                         7                      76.7                     9.6 (5.1--14.1)                                   11.65 (10.2--14.6)
  Kaassis               2000   Retrospective   Proctitis                                 16                         1                      93.8                     na                                                na
  Karamanolis           2009   Prospective     Radiation proctitis                       56                         6                      89.3                     na                                                na
  Latorre               2008   Prospective     Chronic radiation proctopathy             38                         5                      86.8                     11.3 ± 3.05                                       14.014 ± 1.29
  Lenz                  2011   Prospective     Chronic radiation coloproctopathy         15                         1                      93.3                     11.7 ± 2.7                                        13.0 ± 0.9
  Lpoez                 2010   Retrospective   Radiation proctopathy                     19                         1                      94.7                     11.8 (7.3--16.5)                                  12.9 (7.5--16.5)
  Onoyama               2011   Prospective     Chronic hemorrhagic radiation proctitis   24                         0                      100.0                    10 ± 2.2                                          12.3 ± 1.5
  Rolachon A            2000   Prospective     Proctitis and proctosigmoiditis           12                         1                      91.7                     7.9 ± 2.1                                         11 ± 1.4
  Rotondano             2003   Prospective     Chronic radiation proctopathy             24                         2                      91.7                     9.2 ± 2.4                                         13.6 ± 1.1
  Sait Dag              2013   Retrospective   Radiation proctitis                       21                         3                      85.7                     na                                                na
  Samy                  2012   Prospective     Chronic proctitis                         23                         6                      73.9                     na                                                na
  Sarah                 2001   Prospective     Proctitis                                 11                         0                      100.0                    7.7 ± 2.8                                         11.5 ± 2.6
  Sato                  2011   Prospective     Hemorrhagic radiation proctopathy         65                         4                      93.8                     11.1 (5.8--13.3)                                  13.7 (12--15.2)
  Sebastian             2004   Prospective     Radiation proctopathy                     25                         4                      84.0                     10.05 ± 2.21                                      12.44 ± 1.09
  Silva                 1999   Prospective     Proctosigmoiditis                         28                         1                      96.4                     na                                                na
  Smith                 2001   Prospective     Proctitis                                 7                          2                      71.4                     na                                                na
  Swan                  2010   Prospective     Chronic radiation proctitis               49                         1                      98.0                     na                                                na
  Takemoto              2012   Prospective     Hemorrhagic radiation proctopathy         12                         2                      83.3                     na                                                na
  Tam                   2000   Retrospective   Proctitis                                 15                         0                      100.0                    10.8 ± 2.57                                       13.3 ± 1.84
  Tjandra               2001   Prospective     Hemorrhagic proctitis                     12                         6                      50.0                     11.18 ± 0.82                                      12.28 ± 0.55
  Venkatesh             2002   Prospective     Radiation proctitis                       40                         1                      97.5                     na                                                na
  Villavicencio         2002   Prospective     Hemorrhagic radiation proctopathy         21                         0                      100.0                    na                                                na
  Yeoh                  2013   Prospective     Chronic radiation proctitis               17                         1                      94.1                     14 (97--159)                                      13.6 (10.6--17.4)
  Zinicola              2003   Retrospective   Radiation proctitis                       12                         2                      83.3                     na                                                na

###### 

Study characteristics of selected studies on short-term and long-term complications after APC treatment.

  Author                    Proctitis                                 Total number of bleeding   Short-term complications                                                                                         Number of perforations   Long-term complications                                                                        Rate of complications (%)
  ------------------------- ----------------------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------------------------------------------------------- ---------------------------
  Alfadhli                  Prospective                               14                         2 (vomiting, abdominal cramps, rectal pain, and fever)                                                           0                        0                                                                                              14.30
  Álvaro-Villegas           Chronic radiation proctitis               14                         2 (rectal pain)                                                                                                  0                        3 (rectal ulcers)                                                                              35.70
  Ben                       Hemorrhagic radiation proctitis           27                         5 (anal or rectal pain, vagal symptoms, and colonic explosions without perforation in 2 and perforation in 1)    1                        0                                                                                              18.50
  Canard                    Radiation proctitis                       30                         6 (post treatment pain)                                                                                          1                        1 (extensive necrosis of the lower part of the rectum)                                         26.70
  Chruscielewska-Kiliszek   Chronic radiation proctitis               62                         1 (adynamic ileus)                                                                                               0                        35 (asymptomatic rectal ulcer in 30 and symptomatic rectal ulcers in 5)                        58.10
  Chutkan                   Proctitis                                 12                         0                                                                                                                0                        0                                                                                              0.00
  de la Serna Higuera       Hemorrhagic radiation proctopathy         10                         0                                                                                                                0                        0                                                                                              0.00
  Dees                      Chronic radiation proctitis               48                         0                                                                                                                0                        1 (recurrence of rectal bleeding)                                                              2.00
  Fantin                    Proctitis                                 7                          0                                                                                                                0                        0                                                                                              0.00
  Hortelano E               Chronic radiation proctitis               30                         1 (incontinence)                                                                                                 0                        1 (rectal ulcer)                                                                               6.67
  Kaassis                   Proctitis                                 16                         4 (transitory and minimal dysenteric)                                                                            0                        1 (recurrence of rectal bleeding)                                                              31.30
  Karamanolis               Radiation proctitis                       56                         1 (colonic explosion without perforation)                                                                        0                        2 (recurrence of rectal bleeding)                                                              5.4
  Latorre                   Chronic radiation proctopathy             38                         na                                                                                                               na                       0                                                                                              0.00
  Lenz                      Chronic radiation coloproctopathy         15                         4 (anal pain in 2 cases and abdominal discomfort in 1, worsening of bleeding during treatment in 1)              0                        2 (tapered feces without stenosis in 1, asymptomatic stenosis in 1)                            40.00
  Lpoez                     Radiation proctopathy                     19                         0                                                                                                                0                        1 (recurrence of rectal bleeding)                                                              5.30
  Onoyama                   Chronic hemorrhagic radiation proctitis   24                         0                                                                                                                0                        0                                                                                              0.00
  Rolachon A                Proctitis and proctosigmoiditis           12                         0                                                                                                                0                        3 (chronic rectal ulcerations in 2 cases and rectal stenosis in 1 case)                        25.00
  Rotondano                 Chronic radiation proctopathy             24                         5 (mild bloating, cramping, anal pain)                                                                           0                        1 (rectal stenosis)                                                                            25.00
  Sait Dag                  Radiation proctitis                       21                         4 (rectal pain and distension)                                                                                   0                        1 (recurrence of rectal bleeding)                                                              23.80
  Samy                      Chronic proctitis                         23                         na                                                                                                               na                       0                                                                                              0.00
  Sarah                     Proctitis                                 11                         0                                                                                                                0                        7 (rectal stenosis in 2 patients, ulceration in 1, asymptomatic superficial ulceration in 4)   63.60
  Sato                      Hemorrhagic radiation proctopathy         65                         8 (rectal pain)                                                                                                  0                        4 (recurrence of rectal bleeding)                                                              18.50
  Sebastian                 Radiation proctopathy                     25                         0                                                                                                                0                        0                                                                                              0.00
  Silva                     Proctosigmoiditis                         28                         3 (transient anal pain)                                                                                          0                        0                                                                                              10.70
  Smith                     Proctitis                                 7                          0                                                                                                                0                        0                                                                                              0.00
  Swan                      Chronic radiation proctitis               49                         17 (proctalgia in 13 patients, rectal mucous discharge in 4, incontinence in 1, fever in 1, and bleeding in 1)   0                        1 (rectal stricture)                                                                           36.00
  Takemoto                  Hemorrhagic radiation proctopathy         12                         0                                                                                                                0                        0                                                                                              0.00
  Tam                       Proctitis                                 15                         0                                                                                                                0                        2 (rectal stricture)                                                                           13.30
  Tjandra                   Hemorrhagic proctitis                     12                         0                                                                                                                0                        0                                                                                              0.00
  Venkatesh                 Radiation proctitis                       40                         0                                                                                                                0                        0                                                                                              0.00
  Villavicencio             Hemorrhagic radiation proctopathy         21                         3 (rectal pain, tenesmus, and/or abdominal distention)                                                           0                        1 (recurrence of rectal bleeding)                                                              19.00
  Zinicola                  Radiation proctitis                       12                         0                                                                                                                0                        1 (rectosigmoid stenosis)                                                                      7.10

###### 

Newcastle-Ottawa Scale for assessing quality of cohort studies.

  Quality assessment scale   1   2   3   4    5    6    Total (max = 6)
  -------------------------- --- --- --- ---- ---- ---- -----------------
  Ben (2004)                 ∗   ∗   ∗   ∗    ∗    ∗    6
  Canard (2003)              ∗   ∗   ∗   ∗    ∗    ∗    6
  Chruscielewska (2013)      ∗   ∗   ∗   ∗    ∗    ∗    6
  Chutkan (1997)             ∗   ∗   ∗   ∗    ∗    ∗    6
  Higuera (2006)             ∗   ∗   ∗   \-   ∗    ∗    5
  Dees (1999)                ∗   ∗   ∗   ∗    ∗    \-   5
  Fantin (2004)              ∗   ∗   ∗   ∗    ∗    ∗    6
  Hortelano (2014)           ∗   ∗   ∗   ∗    ∗    ∗    6
  Kaassis (2002)             ∗   ∗   ∗   ∗    ∗    ∗    6
  Karamanolis (2009)         ∗   ∗   ∗   ∗    ∗    ∗    6
  Latorre (2008)             ∗   ∗   ∗   ∗    ∗    ∗    6
  Lpoez (2010)               ∗   ∗   ∗   ∗    ∗    ∗    6
  Onoyama (2011)             ∗   ∗   ∗   ∗    ∗    ∗    6
  Rolachon (2000)            ∗   ∗   ∗   ∗    ∗    ∗    6
  Rotondano (2003)           ∗   ∗   ∗   ∗    ∗    ∗    6
  Sait (2013)                ∗   ∗   ∗   ∗    ∗    ∗    6
  Samy (2012)                ∗   ∗   ∗   \-   \-   ∗    4
  Sarah (2001)               ∗   ∗   ∗   ∗    \-   ∗    5
  Sato (2011)                ∗   ∗   ∗   ∗    ∗    ∗    6
  Sebastian (2004)           ∗   ∗   ∗   \-   ∗    ∗    5
  Silva (1999)               ∗   ∗   ∗   ∗    ∗    ∗    6
  Smith (2001)               ∗   ∗   ∗   ∗    \-   ∗    5
  Swan (2010)                ∗   ∗   ∗   ∗    ∗    ∗    6
  Takemoto (2012)            ∗   ∗   ∗   ∗    ∗    ∗    6
  Tam (2000)                 ∗   ∗   ∗   ∗    ∗    ∗    6
  Tjandra (2001)             ∗   ∗   ∗   ∗    ∗    ∗    6
  Venkatesh (2002)           ∗   ∗   ∗   \-   \-   ∗    4
  Villavicencio (2002)       ∗   ∗   ∗   ∗    ∗    ∗    6
  Zinicola (2003)            ∗   ∗   ∗   ∗    ∗    ∗    6

1: representativeness of the exposed cohort; 2: ascertainment of APC exposure; 3: demonstration that outcome of interest was not present at start of study; 4: assessment of outcome; 5: was follow-up long enough for outcomes to occur; 6: adequacy of follow-up of cohorts. Asterisk (∗) indicated one score and hyphen (-) indicated zero score.
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